There’s now an innovative way for people living with the blood cancer, chronic myeloid leukaemia (CML) to support vitally needed medical research.

For Benefits Medicine (FBM) supports the Leukaemia Foundation through a partnership where 100% of profits from an generic drug called cipla imatinib will be invested into important blood cancer research.

This drug, used to treat chronic myeloid leukaemia (CML), is approved and meets the same strict quality and safety regulations applied to the original brand of imatinib regarding quality, safety and effectiveness.

“By going generic, people living with CML can make a significant contribution to our patient support and research. We encourage individuals to have considered discussion with their family and haematologist before making the switch,” said a Leukaemia Foundation spokesperson.

Find out how to make the switch at www.forbenefitmedicines.com.au.